JP2023522156A5 - - Google Patents

Info

Publication number
JP2023522156A5
JP2023522156A5 JP2022560285A JP2022560285A JP2023522156A5 JP 2023522156 A5 JP2023522156 A5 JP 2023522156A5 JP 2022560285 A JP2022560285 A JP 2022560285A JP 2022560285 A JP2022560285 A JP 2022560285A JP 2023522156 A5 JP2023522156 A5 JP 2023522156A5
Authority
JP
Japan
Prior art keywords
amino acid
sequence
item
seq
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522156A (ja
Filing date
Publication date
Priority claimed from GBGB2004826.0A external-priority patent/GB202004826D0/en
Priority claimed from GBGB2010672.0A external-priority patent/GB202010672D0/en
Priority claimed from GBGB2015775.6A external-priority patent/GB202015775D0/en
Priority claimed from GBGB2101824.7A external-priority patent/GB202101824D0/en
Priority claimed from GBGB2103214.9A external-priority patent/GB202103214D0/en
Application filed filed Critical
Priority claimed from PCT/GB2021/050830 external-priority patent/WO2021198706A2/en
Publication of JP2023522156A publication Critical patent/JP2023522156A/ja
Publication of JP2023522156A5 publication Critical patent/JP2023522156A5/ja
Priority to JP2025162640A priority Critical patent/JP2025184979A/ja
Pending legal-status Critical Current

Links

JP2022560285A 2020-04-01 2021-04-01 コロナウイルスワクチン Pending JP2023522156A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025162640A JP2025184979A (ja) 2020-04-01 2025-09-29 コロナウイルスワクチン

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB2004826.0 2020-04-01
GBGB2004826.0A GB202004826D0 (en) 2020-04-01 2020-04-01 Coronavirus vaccines
GBGB2010672.0A GB202010672D0 (en) 2020-07-10 2020-07-10 Coronovirus vaccines
GB2010672.0 2020-07-10
GBGB2015775.6A GB202015775D0 (en) 2020-10-05 2020-10-05 Coronavirus vaccines
GB2015775.6 2020-10-05
GB2101824.7 2021-02-10
GBGB2101824.7A GB202101824D0 (en) 2021-02-10 2021-02-10 Coronavirus vaccines
GB2103214.9 2021-03-08
GBGB2103214.9A GB202103214D0 (en) 2021-03-08 2021-03-08 Coronavirus vaccines
PCT/GB2021/050830 WO2021198706A2 (en) 2020-04-01 2021-04-01 Coronavirus vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025162640A Division JP2025184979A (ja) 2020-04-01 2025-09-29 コロナウイルスワクチン

Publications (2)

Publication Number Publication Date
JP2023522156A JP2023522156A (ja) 2023-05-29
JP2023522156A5 true JP2023522156A5 (https=) 2024-05-08

Family

ID=75426636

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022560285A Pending JP2023522156A (ja) 2020-04-01 2021-04-01 コロナウイルスワクチン
JP2025162640A Pending JP2025184979A (ja) 2020-04-01 2025-09-29 コロナウイルスワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025162640A Pending JP2025184979A (ja) 2020-04-01 2025-09-29 コロナウイルスワクチン

Country Status (7)

Country Link
US (1) US20240285751A1 (https=)
EP (1) EP4126033A2 (https=)
JP (2) JP2023522156A (https=)
CN (1) CN116113431A (https=)
AU (1) AU2021249525A1 (https=)
CA (1) CA3179038A1 (https=)
WO (1) WO2021198706A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103231A4 (en) 2020-02-14 2024-03-27 Geovax, Inc. VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2
CN113527444B (zh) * 2020-04-13 2022-12-27 中国科学院微生物研究所 与新型冠状病毒的抗体有效结合的表位
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
US20240293534A1 (en) * 2021-06-14 2024-09-05 Modernatx, Inc. Coronavirus glycosylation variant vaccines
EP4183409A1 (en) * 2021-11-17 2023-05-24 Charité - Universitätsmedizin Berlin Vaccine with improved immunogenicity against mutant coronaviruses
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
JP2026508394A (ja) 2023-03-03 2026-03-10 ディオシンバックス リミテッド コロナウイルスワクチン
EP4687969A1 (en) * 2023-04-05 2026-02-11 DIOSynVax Ltd Coronavirus vaccines inducing broad immunity against variants
WO2025083402A1 (en) * 2023-10-16 2025-04-24 Diosynvax Ltd Coronavirus vaccines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG128680A1 (en) * 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
WO2005077103A2 (en) * 2004-02-12 2005-08-25 Regents Of The University Of Colorado Compositions and methods for modification and prevention of sars coronavirus infectivity
CN1884303A (zh) * 2005-06-20 2006-12-27 中国医学科学院基础医学研究所 SARS－CoV病毒结构蛋白的融合蛋白及其高量表达与纯化和用途
CN102690336A (zh) * 2012-06-11 2012-09-26 中国科学院武汉病毒研究所 蝙蝠sars样冠状病毒刺突蛋白免疫决定区及制备方法和用途
WO2015143335A1 (en) * 2014-03-20 2015-09-24 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
CN106928326B (zh) * 2015-12-31 2019-12-24 中国科学院微生物研究所 一种基于二聚化的受体结合区亚单位的冠状病毒疫苗
WO2019169120A1 (en) * 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
US11918643B2 (en) * 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants

Similar Documents

Publication Publication Date Title
JP2023522156A5 (https=)
Palmer et al. Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes
JP2025184979A (ja) コロナウイルスワクチン
AU2021218141B2 (en) HIV vaccines comprising one or more population episensus antigens
US20190307879A1 (en) Adenovirus-vectored multivalent vaccine
US7790169B2 (en) Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus
US11872276B2 (en) Zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
CN101805393A (zh) Replikin肽及其应用
CN113666990A (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
CN1982332A (zh) Hiv调节/辅助蛋白的融合蛋白
US10251948B2 (en) Anti-HIV vaccine constructed based on amino acid mutations in attenuated live EIAV vaccine
CN115867313A (zh) 作为疫苗抗原的工程化冠状病毒刺突蛋白、其设计和用途
CN113980100B (zh) 一种腺病毒载体重组新冠病毒b.1.429变异株疫苗及其应用
CN108210921A (zh) 一种寨卡病毒疫苗及其制备方法
CN114106116B (zh) 一种腺病毒载体重组新冠病毒b.1.617.2变异株疫苗及其应用
CN105671064B (zh) 抗猪繁殖与呼吸综合症病毒感染的重组抗原基因、重组抗原蛋白及亚单位疫苗组合物
Zakhartchouk et al. Optimization of a DNA vaccine against SARS
McCabe et al. Potential for broad-spectrum protection against feline calicivirus using an attenuated myxoma virus expressing a chimeric FCV capsid protein
Monastyrskaya et al. Characterization and modification of the carboxy-terminal sequences of bluetongue virus type 10 NS1 protein in relation to tubule formation and location of an antigenic epitope in the vicinity of the carboxy terminus of the protein
Borrego et al. A highly divergent antigenic site of foot-and-mouth disease virus retains its immunodominance
Guo et al. Recombinant adenovirus expression of FMDV P1-2A and 3C protein and its immune response in mice
AU731911B2 (en) Use of a polypeptide as cellular receptor for adenoviruses
DE69534945T2 (de) Impfstoff für die infektiöse peritonitis der katzen
WO2023031306A2 (en) New coronavirus vaccine and method for designing and obtaining a virus vaccine
US11723968B2 (en) Stabilized recombinant hantaviral spike proteins comprising mutations in Gc